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According to the guidelines of the European Stroke Organization (ESO) and the American
Stroke Association (ASA), acute stroke patients should be managed at stroke units that
include well organized pre- and in-hospital care. In ischemic stroke the restoration of blood
ﬂow has to occur within a limited time window that is accomplished by ﬁbrinolytic therapy.
Newer generation thrombolytic agents (alteplase, pro-urokinase, reteplase, tenecteplase,
desmoteplase) have shorter half-life and are more ﬁbrin-speciﬁc. Only alteplase has Food
and Drug Administration (FDA) approval for the treatment of acute stroke (1996). The
National Institute of Neurological Disorders and Stroke (NINDS) trial proved that alteplase
was effective in all subtypes of ischemic strokes within the ﬁrst 3h. In the European coop-
erative acute stroke study III trial, intravenous (IV) alteplase therapy was found to be safe
and effective (with some restrictions) if applied within the ﬁrst 3–4.5h. In middle cere-
bral artery (MCA) occlusion additional transcranial Doppler insonication may improve the
breakdown of the blood clot. According to the ESO and ASA guidelines, intra-arterial (IA)
thrombolysis is an option for recanalization within 6h of MCA occlusion. Further trials on
the IA therapy are needed, as previous studies have involved relatively small number of
patients (compared to IV trials) and the optimal IA dose of alteplase has not been deter-
mined (20–30mg is used most commonly in 2h). Patients undergoing combined (IV+IA)
thrombolysis had signiﬁcantly better outcome than the placebo group or the IV therapy
alone in the NINDS trial (Interventional Management of Stroke trials). If thrombolysis fails
or it is contraindicated, mechanical devices [e.g., mechanical embolus removal in cerebral
ischemia (MERCI)- approved in 2004] might be used to remove the occluding clot. Stenting
can also be an option in case of acute internal carotid artery occlusion in the future. An
intra-aortic balloon was used to increase the collateral blood ﬂow in the Safety and Efﬁcacy
of NeuroFlo™ Technology in Ischemic Stroke trial (results are under evaluation). Currently,
there is no approved effective neuroprotective drug.
Keywords: intravenous thrombolysis, intra-arterial thrombolysis, acute stroke, mechanism of recanalization,
thrombectomy, alteplase, stroke unit, therapeutic time window
INTRODUCTION
Stroke is the third most common cause of death and it is the most
commonly disabling disease. The care of stroke patients is chal-
lenging, because there is no easy method to rapidly establish the
diagnosis at the patient’s home like in some of the acute myocar-
dialinfarctioncases(e.g.,EEG).Itisalsoimpossibletodistinguish
hemorrhagicstrokesfromischemicstrokesbasedsolelyonclinical
symptoms; for that a brain CT must be performed. The time win-
dow for therapy is short and none of the neuroprotective agents
have been proven to be effective yet.
The effective treatment of ischemic strokes today relies on
rapid mechanical endovascular or pharmacological revascular-
ization of the affected areas. The 1995 National Institute of
Neurological Disorders and Stroke (NINDS) trial represented a
breakthrough, as it was the ﬁrst to prove in a randomized study
thatﬁbrin-speciﬁcagentscouldleadtobothrevascularizationand
clinicalimprovementinallsubtypesof ischemicstroke,advancing
stroke therapy beyond the previously used non-ﬁbrin-speciﬁc
drugs (The National Institute of Neurological Disorders and
Stroke rt-PA Stroke Study Group, 1995). tissue type-plasminogen
activator (t-PA) was approved by the Food and Drug Administra-
tion(FDA)in1996andiswidelyusedforthetreatmentofischemic
strokes.
Because pharmacological thrombolysis is not 100% success-
ful, mechanical thrombectomy has also attracted attention in the
last few years. These techniques use intra-arterial (IA) devices to
removetheclotorscleroticdebrisfromtheoccludedartery,which
remain insoluble following thrombolysis.
In this review we discuss the:
• importance of early revascularization in acute ischemic stroke,
• experience with ﬁbrinolytics,
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• methods of intravenous (IV), IA, and combined (IV+IA)
thrombolysis,
• recent results with mechanical revascularization (recanaliza-
tion) techniques.
TIME IS OF ESSENCE: THE IMPORTANCE OF EARLY
REVASCULARIZATION (RECANALIZATION)
The size of the ischemic lesion is proportional to the caliber of the
occludedartery,andtothedurationof theocclusion,andwillonly
be reduced by the blood ﬂow available through the collaterals. A
general rule (with many exceptions) is that distal occlusions (e.g.,
middle or anterior cerebral artery) have a higher risk for cerebral
infarction than proximal ones [e.g.,internal carotid artery (ICA)]
because the latter has more collateral blood ﬂow available to com-
pensate. A sudden arterial occlusion triggers the development of
the ischemic cascade.
Decreased blood perfusion of the brain results in oxygen and
glucose deﬁcit. The consequences are extracellular calcium and
sodium inﬂux into the intracellular space and potassium efﬂux.
Calcium inﬂux activates lipase enzymes and the release of exci-
tatory amino acids. Neurotransmitters and free radicals are pro-
ducedfollowedbycytokinereleaseandseveraladditionalcatabolic
mechanisms are induced. Intracellular ion changes occur within a
short time;this phenomenon can be used for detecting the abnor-
mal cellular water movement within minutes of the symptom
onset of ischemic strokes using diffusion MRI (Kuroiwa et al.,
2007).
Therapeutic strategies were signiﬁcantly altered by the devel-
opment of the theory of the “ischemic penumbra” (Figure 1).
This hypothesis does not consider the ischemic region a homo-
geneous dead tissue with sharp edges separated from the intact
tissue (Astrup et al., 1981; Csiba et al., 1983, 1985). Rather, only
the ischemic core, where the blood ﬂow is below the critical value
of 7.7–14ml/100g/min, is considered to be irreversibly damaged.
The region surrounding this area has functional deﬁcit (“elec-
tric silence”) with otherwise preserved integrity of the tissues
(ischemic penumbra) and is an area at risk. This is the area we
aim to salvage during stroke interventions. The success of our
rescue efforts will depend on the duration of the ischemia, on the
degreeofrevascularizationandonadditionalfactorssuchasblood
pressure, serum glucose, etc. (Segura et al.,2008).
FIGURE 1 | Structure of the ischemic penumbra.
Both animal and human studies proved that the size of the
penumbra (the salvageable area at risk) is shrinking as time goes
on while the area of permanent damage is expanding. Therefore
recanalization of the occluded artery should happen within a few
hours after the onset of the focal ischemic stroke, otherwise 120
million neurons, 830 billion synapses, and 714km axons die each
hour (Saver,2006).
FIBRINOLYTIC DRUGS
Agents available for IV or IA thrombolysis are: streptokinase,
urokinase, alteplase, pro-urokinase, reteplase, tenecteplase, and
desmoteplase.
FIRST GENERATION FIBRINOLYTICS (STREPTOKINASE, UROKINASE)
These agents only have historical importance (Cornu et al.,2001).
They are not ﬁbrin-speciﬁc. They induce ﬁbrinolysis but they
also decrease the level of ﬁbrinogen, coagulation factors, and von
Willebrand factor in the blood. Streptokinase,an enzyme secreted
by several species of streptococci, can activate human plasmino-
gen. Since it has immunological side effects (allergic reactions)
and increases the risk of intracranial hemorrhage, it is no longer
used for thrombolysis. Urokinase was also tested for both IV and
IA thrombolysis, but it has not signiﬁcantly improved clinical
outcomes (Murray et al.,2010).
SECOND GENERATION FIBRINOLYTICS (ALTEPLASE, PRO-UROKINASE)
Alteplase and pro-urokinase are more ﬁbrin-speciﬁc and have
no immunological side effects compared to the previous group.
Alteplase (rt-PA) is the only FDA approved ﬁbrinolytic drug in
acute ischemic stroke. It has a short half-life (4–6min) but unfor-
tunately it also has some neurotoxic side effects by activating a
metalloproteinase. This enzyme modulates the blood–brain bar-
rier, which results in an increased risk for intracerebral bleeding
and brain edema (Micieli et al.,2009).
Pro-urokinase (half-life 7min) has been also tested in clin-
ical trials, but unfortunately despite the good clinical results it
has not received FDA approval yet. The prolyse in acute cerebral
thromboembolismII(PROACTII)trial(FurlanandAbou-Chebl,
2002) compared the efﬁcacy of IA pro-urokinase treatment with
IV heparin in middle cerebral artery (MCA) occlusion. Recanal-
izationratewas66%inthepro-urokinase,and18%intheheparin
group,while40%of thecasesinthepro-urokinaseand25%inthe
heparin group had good clinical outcome (less than two on the
modiﬁed Rankin Scale; Furlan and Abou-Chebl, 2002)( Table 3).
THIRD GENERATION FIBRINOLYTICS (RETEPLASE, TENECTEPLASE)
Since rt-PA might damage the blood–brain barrier, there are fur-
ther efforts for developing ﬁbrinolytics with fewer side effects.
Reteplase and tenecteplase are modiﬁed forms of alteplase with
longer half-life and have only been applied in trials yet.
The ﬁrst prospective human clinical trial evaluated the safety
and efﬁcacy of IA reteplase treatment in 16 patients with ischemic
stroke who were poor candidates for IV alteplase therapy. Near
complete or complete recanalization was observed after treatment
in 88% of the patients (Qureshi et al., 2002).
In a preliminary safety trial different doses of IA reteplase
were combined with IV administered abciximab (platelet aggre-
gation inhibitor, glycoprotein IIb/IIIa). The patients were treated
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between 3 and 6h following the onset of their symptoms. There
was one symptomatic intracerebral hemorrhage and 13 success-
fulrecanalizationamongthe20patientstreated.Thirteenpatients
demonstrated early neurological improvement and favorable out-
come was observed in six patients after 1month (Qureshi et al.,
2006).
Tenecteplase has a longer half-life (17min) and is more
ﬁbrin-speciﬁc than alteplase.
Inanotherstudy,low-dosetenecteplase(0.1mg/kg)wasapplied
IVinasmallgroupofpatients(N =15)between3and6hafterthe
onsetof cerebralarterialocclusion;patientshadaperfusiondeﬁcit
ofatleast20%largerthantheinfarctcore(perfusion/angiographic
CT/MR). Their results were compared to the outcome of 35
patients treated within the ﬁrst 3h with rt-PA following the stan-
dard selection criteria (Parsons et al., 2009). Tenecteplase showed
signiﬁcantly higher recanalization rate compared to alteplase (74
vs. 44%). Despite the fact that the treatment was started later and
thesymptomsweremoresevereinthetenecteplase-group,patients
showed better improvement at 24h after the therapy than those
patients who were treated with alteplase. Four of the alteplase
treated patients and none of the tenecteplase treated patients had
parenchymal hematoma at 24h.
Haley et al. (2005) found the dose of 0.1–0.4mg/kg of
tenecteplase safe to be used in acute stroke. Eighty-eight patients
were treated within the ﬁrst 3h. The lower doses of tenecteplase
(0.1, 0.2, or 0.4mg/kg) caused only asymptomatic intracerebral
bleeding (in 8–32% of the cases in the separated subgroups),
while the higher doses (0.5mg/kg) caused both asymptomatic
and symptomatic intracerebral bleeding (in 13 and 23% of the
13 treated patients). According to the modiﬁed Rankin scale
tenecteplase showed similar results as alteplase at the 3-month
follow-up period.
FOURTH GENERATION OF FIBRINOLYTICS (DESMOTEPLASE)
The fourth generation ﬁbrinolytics are produced by genetic
methods.
Desmoteplase (more ﬁbrin-speciﬁc, has no neurotoxicity) has
been tested in the desmoteplase in acute stroke (DIAS) 2–4 tri-
als (Paciaroni et al., 2009). DIAS was a randomized, placebo-
c o n t r o l l e dt r i a lw i t ha3t o9 - ht i m ew i n d o w( Hacke et al., 2005)
for treatment eligibility. Patients with moderate symptoms and
diffusion/perfusion mismatch on the MRI were randomized into
placebo and ﬁx dose of IV desmoteplase groups. A symptomatic
intracranial hemorrhage was observed in 30.8% of the patients in
the high-dose (37.5 or 50mg) and 23.5% of the patients in the
low-dose (25mg) group in the ﬁrst part of the trial. Subsequently,
the study was continued with considerably lower dosages (90 and
125μg/kg). There the occurrence of symptomatic intracranial
bleeding in the desmoteplase group was found to be only 2.2%.
However,theresultsof DIAS-2trialcouldnotsupportthesefavor-
able ﬁndings. In the DIAS-2 trial almost 200 patients were ran-
domizedintogroupstreatedwithdifferentdosesof desmoteplase.
Inclusioncriteriaofthepatientswasdiffusion/perfusionmismatch
on MR/CT. Treatment was initiated between 3 and 9h after the
onset of stroke. Unfortunately, neither the 90 nor the 125-μg/kg
dosages were found to be effective. Additionally, mortality was
higher in the group treated with 125μg/kg compared to both the
placebo-treatedgroupandthegroupwhichreceivedthe90-μg/kg
dose (Liebeskind, 2009). The rate of bleeding was 4.5% in the
higher dose and 3.5% in the lower dose treatment group and 0%
in the placebo group. The DIAS-3 and -4 trials are still ongoing.
They are comparing the effect of placebo with IV desmoteplase
treatment(90μg/kgdose)givenbetweentheﬁrst3–9hafteracute
stroke.
In conclusion: at present the evidence is strongest for alteplase
to be a clinically effective ﬁbrinolytic in acute stroke, but research
is still ongoing to ﬁnd a more ﬁbrin-speciﬁc agent with shorter
half-life and less neurotoxic side effects.
INTRAVENOUS FIBRINOLYSIS IN THE CLINICAL PRACTICE
The NINDS trial produced a real breakthrough in ﬁbrinolytic
therapy. It proved the efﬁcacy of rt-PA (alteplase) therapy in all
subtypes of ischemic stroke. It also proved that the beneﬁts of
thrombolysis (rt-PA) extend beyond 1year after the treatment
(Kwiatkowski et al., 1999).
However, the 3-h time window for treatment has proven to be
too short in clinical practice. Therefore, several subsequent stud-
ies have investigated the feasibility of a wider, but still safe time
window.
The results of European cooperative acute stroke study
(ECASS-III), a placebo-controlled trial, using IV rt-PA in the 3 to
4.5-h time window, were published in 2008 (Saver et al., 2009).
This placebo-controlled trial proved the safety of IV thromboly-
sis within the ﬁrst 3–4.5h following ischemic stroke with patient
listed below excluded from the trial.
• Younger than 18 or older than 80years
• Severe neurological symptoms National Institute of Health
Stroke Scale (NIHSS) >25
• Taking anticoagulant (irrespectively of hemostatic parameters)
• History of diabetes mellitus and a previous stroke
In this study excellent clinical outcomes (0 or 1 point on the mod-
iﬁed Rankin Scale) were more frequent in the rt-PA treated group
than in the placebo group (52 vs. 45%, p =0.04) 3months after
treatment. The mortality in the rt-PA treated group was not sig-
niﬁcantlydifferentfromthatof placebogroup(17%inthetreated
group a 21% in the placebo group).While,symptomatic intracra-
nial bleedings were more frequent in the t-PA group (2.4 vs. 0.2%,
p =0.001).
BeforeinitiatingIVthrombolysis,thecost-beneﬁtratiomustbe
calculated. The inclusion and exclusion criteria must be followed
strictly (Table 2). When doing so, one has to bear in mind that 32
patientsoutof 100thrombolysedwilllikelytoshowimprovement
and only three is likely to have harm (Saver, 2004). Follow-up
studies also support the fact: the earlier the thrombolysis is per-
formed the better clinical improvement can be achieved. One of
two patients will likely become symptom-free or have minimal
residual symptoms if treated with IV thrombolysis (Marler et al.,
2000; Saver et al., 2010) within the ﬁrst hour following a stroke.
Thisratiodropsto1outof 4if treatedbetween60and90minafter
the onset of stroke, and 1 out of 9 between the ﬁrst 90–180min,
further diminishing to 1 out of 21 patients if treatment is delayed
to 180–270min. Time lost is brain lost!
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Table 1 | Recommendations for the speciﬁc treatment of acute
ischemic stroke.
Intravenous rt-PA (0.9mg/kg body weight, max. 90mg) is recommended
within the ﬁrst 3h (in selected cases also between the ﬁrst 3 and 4.5h)
of the ischemic stroke. 10% of the calculated dose is given as an iv. bolus
injection, 90% is given under 60 minutes as an iv. infusion.
Lower blood pressure under 185/110mmHg before initiating thrombolysis.
Intravenous rt-PA may be used in patients with seizures at stroke onset, if
the neurological deﬁcit is related to acute cerebral ischemia.
Age: intravenous rt-PA may also be administered in selected patients under
18years and over 80years of age.
Intra-arterial treatment of acute MCA occlusion within a 6-h time window
with rt-PA is an option.
Acute basilar occlusion: intra-arterial thrombolysis is recommended for
selected patients and intravenous thrombolysis is acceptable even after 3h.
If thrombolytic therapy is given antithrombotic therapy should not be ini-
tiated within 24h, but Aspirin (160–325mg loading dose) should be given
within the ﬁrst 48h of ischemic stroke.The use of other antiplatelet drug is
not accepted in acute stroke.
Earlyadministrationofunfractionatedheparin,lowmolecularweightheparin
is not recommended.
TheEuropeanStrokeOrganization:guidelinesformanagementofischemicstroke
and transient ischemic attack 2008.
Therefore medical systems must have a “fast lane” for patients
arriving to the hospital for thrombolysis. The optimal time win-
dowforcompletingdiagnosticworkupandinitiatingIVtreatment
should not exceed 60min.
The recommended dose of rt-PA used IV is 0.9mg/kg. A max-
imum total dose of 90mg can be given. Ten percent of this must
be injected in a bolus. The rest should be administered within the
nexthour(Table 1).Thepatientcannotreceiveantiplateletoranti-
coagulant drugs within the ﬁrst 24h if thrombolysis was applied.
One day after thrombolysis a cranial CT must be performed to
detect intracranial bleed.
ULTRASOUND-ENHANCED INTRAVENOUS THROMBOLYSIS
Alexandrov (Molina et al., 2004) used a commercially available,
2MHz transcranial Doppler ultrasound (TCD) to facilitate the
effect of rt-PA and to improve revascularization (recanalization)
rate during IV thrombolysis for arterial occlusion. Ultrasound
(US) enhances the interaction between rt-PA and ﬁbrin. The
vibration and the thermal effects improve the breakdown of the
clot. The 2-MHz US penetrates through the cranial bone, visu-
alizes the intracranial arteries and measures the direction and
speed of the blood ﬂow in the vessels. According to his obser-
vations (Alexandrov, 2010a), complete or partial recanalization
occurred in 83% of the US-enhanced thrombolysis cases whereas
the rate of recanalization was 50% when IV thrombolysis was
used alone. Symptomatic intracranial bleeding occurred in 3.8%
of both groups. Neurological outcome at 3months was also better
(51%) in the US-enhanced group compared to the group with IV
thrombolysis alone (37%).
It is almost a futuristic idea to enhance thrombolysis with
both US sonication and micro bubbles. Five micrometer size
micro bubbles can be given intraveniously. The microbubbles are
destroyed by the US applied through the temporal bone window.
This mechanical interaction can further enhance thrombolysis.
In a recent trial 111 patients with acute MCA occlusion were
treated with some combination of these interventions. Thirty-
eight patients were treated with rt-PA plus continuous 2h long
TCD monitoring plus galactose-based micro bubbles. The rest
of the patients received rt-PA plus continuous 2h TCD–US
insonation (N =37) or t-PA plus placebo monitoring (N =36).
Successfulrevascularizationwasseenin55%ofthosepatientswho
received all three interventions (including micro bubbles). The
revascularization rate was 41% for those who received rt-PA and
additionalTCDsonicationtherapy,and24%forthosewhounder-
wentrt-PAtherapyalone.Morethan56%of thepatientsreceiving
combined treatment, including micro bubbles, showed excel-
lent clinical improvement (improved >4 points on NIHSS) by
1day after treatment vs. those receiving rt-PA+TCD–US therapy
(41%) and conventional thrombolysis alone (31%; Molina et al.,
2006). Despite the promising results, sono-thrombolysis is still
considered to be an experimental method. The efﬁcacy depends
on the presence of the bone window (10–15% of patients, espe-
cially women cannot be effectively sonicated), and the technique
is also operator dependent.
INTRAVENOUS THROMBOLYSIS OUTSIDE OF THE TIME
WINDOW
The new MRI techniques (diffusion MRI and the combination of
MRI and CT) may help in the selection of patients who might
beneﬁt from thrombolysis even after 3 or 4.5h after the onset
of stroke. (Note: if the diffusion deﬁcit is small and the perfu-
sion deﬁcit is large, a diffusion–perfusion mismatch exists and it
might be still worth initiating thrombolysis). Based on such strat-
egy, 72 patients were treated between 3 and 6h after the onset of
strokewithIVrt-PAinthediffusion-weightedimagingevaluation
for understanding stroke evolution (DEFUSE) trial (Olivot et al.,
2009). Those patients who had a diffusion–perfusion mismatch
beneﬁted from the treatment. Half of the 72 patients enrolled
did not have a diffusion–perfusion mismatch and those did not
beneﬁt from the thrombolysis. It was also found, that permeabil-
ity changes detected on MRI can also forecast the appearance of
hemorrhagic complications after rt-PA treatment (Kakuda et al.,
2008).
Anothertrialechoplanarimagingthrombolysisevaluationtrial
(EPITHET), also used perfusion and diffusion MRI to enroll
patients for rt-PA treatment 3–6h after stroke. The IV rt-PA
decreased the size of irreversibly damaged areas and improved
clinical outcome of those patients who had a diffusion–perfusion
mismatch on the MRI before the intervention (Davis et al.,2008).
The beneﬁt of extending the period of eligibility for throm-
bolysis to 9h following an acute stroke is being evaluated by the
ongoing extending the time for thrombolysis in emergency neu-
rological deﬁcit (EXTEND)1 clinical trial, using modern imaging
techniques (diffusion, perfusion MRI, perfusion CT; Wintermark
et al.,2008).
1www.strokecenter.org/trials/TrialDetail.aspx?tid(1059
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Table 2 | Guidelines for the early management of adults with ischemic stroke (AHA/ASA Guideline).
Inclusion criteria Exclusion criteria
It is ischemic stroke causing the symptoms Symptoms are clearing spontaneously
Patients with major deﬁcits should be treated with caution Neurological signs are minor and isolated
Thrombolysis may be used in patients with seizures at the time of
presentation when evidence suggests that residual deﬁcits are due to
ischemia rather than the postictal state
Patient had a seizure and has most likely a postictal residual
neurological impairments
Thrombolysis can be initiated within the time window Head trauma, stroke, or myocardial infarction in the previous 3months
Patients on anticoagulant therapy with the INR ≤1.7 Gastrointestinal or urinary tract hemorrhage in previous 21days
APTI is in the normal range Major surgery in the previous 14days
Arterial puncture at a non-compressible site in the previous 7days
History of previous intracranial hemorrhage
Uncontrollable blood pressure over 185/110mmHg
Evidence of active bleeding or acute trauma (fracture)
Patients on anticoagulant therapy with the INR >1.7
Patient received Heparin in the last 48h
APTI: over the normal range
Platelet count <100G/L
Serum glucose level <2.7mmol/L (50mg/dl)
Symptoms are suggestive of subarachnoid hemorrhage
CT shows a hypodensity >1/3 of the cerebral hemisphere
Table 3 | Modiﬁed Rankin Scale
(www.strokecenter.org/trials/scales/rankin).
Score Description
0 No symptoms at all
1 No signiﬁcant disability despite symptoms; able to carry out all
usual duties and activities
2 Slight disability; unable to carry out all previous activities, but able
to look after own affairs without assistance
3 Moderate disability; requiring some help, but able to walk without
assistance
4 Moderately severe disability; unable to walk without assistance
and unable to attend to own bodily needs without assistance
5 Severe disability; bedridden, incontinent and requiring constant
nursing care and attention
6 Death
INTRA-ARTERIAL THROMBOLYSIS
Thefollowingarethetheoreticaladvantagesof IAthrombolysisin
acute ischemic stroke:
• Fibrinolytic agent can be directly injected into the thrombus
• Revascularization is detected immediately
• Lower dose can be given than in case of IV intervention
• The risk of hemorrhage is lower
The Disadvantages of IA thrombolysis:
• More time is needed for the preparations of the procedure
• Collaboration of interventional radiologists is needed
• Higher costs
• Possibility of arterial injuries
Despite the fact that the IA thrombolysis with rt-PA can be an
option for revascularization according to the European Stroke
Organization (ESO) 20082,andAmerican Heart and StrokeAsso-
ciation (Adams et al., 2007) guidelines, further investigations are
recommend to deﬁne the appropriate role for this intervention.
This is because the recent studies included relatively small num-
ber of patients (compared with IV trials) and the optimal dose of
IA therapy has not been determined yet (most common dose IA
20–30mg in 2h). Therefore further trials comparing the efﬁcacy
and safety of IV and IA thrombolysis are needed.
A meta-analysis (27 trials, 1117 patients) claimed that the IA
thrombolysis increased mortality rates and was associated with
worse functional outcome in minor strokes. Furthermore, this
meta-analysis suggests that the aggressive IA therapy in mild
strokes might result in worse outcomes than the natural course
of the disease (Wardlaw et al., 2009).
Recent trials on IA thrombolysis are the following:
In the PROACT I trial (randomized, placebo-controlled) 40
acute stroke patients with MCA occlusion were treated within
the ﬁrst 6h of acute stroke with 6mg pro-urokinase (IA). All
patients received IV heparin as well. Recanalization was successful
in 57% of the patients treated with pro-urokinase and in 14% of
the patients treated with placebo (p =0.017). Bleeding or clinical
decline occurred in 15% of the pro-urokinase and in 7% of the
placebo-treated patients (del Zoppo et al., 1998).
The subsequent PROACT II, a multicenter, randomized trial,
trial examined the effect of IA recombinant pro-urokinase on
MCA revascularization with treatment applied within the ﬁrst
6h of stroke (Furlan et al., 1999). There were 180 patients who
received heparin or heparin +9mg IA pro-urokinase (slow IA
2www.eso-stroke.org/pdf/ESO%20Guidelines_update_Jan_2009.pdf
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infusion under 2h; max. dose was given in each case regardless
of early recanalization). This study showed a 66% recanalization
rate in the pro-urokinase and 18% in the control group. The
non-disabling (0–2 point on the modiﬁed Rankin Scale) 3-month
functional outcome was signiﬁcantly better if pro-urokinase was
used compared to placebo (improvement: 40 vs. 25%, p =0.04).
Intracerebral hemorrhage with neurological deterioration within
24h occurred in 10.9% of the pro-urokinase group and 3.1%
of the controls. Death rates were similar in both groups. This
trial proved the efﬁcacy of pro-urokinase used within the ﬁrst
6h of acute stroke in case of MCA occlusion. The results were
compared to the results of the NINDS trial. The 3-month out-
come was better than in the placebo-arm of the NINDS trial.
The 3-month mortality rates were lower in the PROACT II trial
(16%) compared to the placebo (24%) and the rt-PA treated
(21%) group of the NINDS trial (The National Institute of
Neurological Disorders and Stroke rt-PA Stroke Study Group,
1995).
Another IA urokinase (given in 120,000 IU boluses, total dose
of 600,000 IU within the ﬁrst 6h of acute stroke) trial the so-
calledMCA-embolismlocalﬁbrinolyticinterventiontrial(MELT)
was performed in Japan. Partial or complete recanalization was
achieved in 74% of the subjects treated with urokinase. Favor-
able 3month outcomes, both non-disabling (0–2 points on the
modiﬁed Rankin Scale) and excellent (0–1 point on the modiﬁed
Rankin Scale), were more common in the urokinase group com-
pared to the control group (49.1 vs. 38.6% and 42.1 vs. 22.8%,
p =0.045). Three-month mortality rates (5.3% in the urokinase
and 3.5% in the control group, p =1.00) and the rate of symp-
tomatic intracerebral bleedings (9% in the urokinase and 2% in
the control group, p =0.206) did not differ signiﬁcantly from the
control group. Since rt-PA was just approved in Japan during that
period, the MELT trial was stopped after the enrollment of 114
patients (Ogawa et al., 2007).
A recent meta-analysis (PROACT, PROACT II, and MELT)
showed that IA thrombolysis resulted in better 3-month clini-
cal outcomes. Although partial or complete recanalization was
achieved in a high proportion of subjects (74% in MELT and 66%
in PROACT II), the rate of complete recanalization was low (5%
in MELT, 18% in the treated arm of PROACT II; Saver,2007).
COMBINED (INTRAVENOUS+INTRA-ARTERIAL)
THROMBOLYSIS
ThisprocedureshouldbeginwiththeIVthrombolysisandshould
proceed to IA therapy only if the ﬁrst intervention fails to accom-
plish revascularization. If the IA procedure also fails, the phar-
macological procedure may be complemented with a mechanical
thrombectomy.
The emergency management of stroke (EMS) trial compared
the efﬁcacy of combined (IV+IA) thrombolysis with IA throm-
bolysis alone started within the ﬁrst 3h of stroke (enrolled 35
patients). The results showed higher recanalization rates with
combined (IV+IA) thrombolysis, but no difference between the
two groups in the clinical improvement. Hemorrhagic trans-
formation was seen more often if combined therapy was used
(Lewandowski et al., 1999).
Intheinterventionalmanagementofstroke(IMS)trialpatients
with arterial occlusion, conﬁrmed by angiography, were treated
withintheﬁrst3hof strokewith0.6mg/kgrt-PAIV.If needed,the
IV treatment was complemented with IA rt-PA (max. 22mg/2h
directly into the thrombus) treatment. Results were compared to
primary results of placebo or IV rt-PA therapy from the NINDS
trial. The 3-month mortality in IMS subjects (16%) was lower
but not statistically different than the mortality of placebo (24%)
and rt-PA-treated subjects (21%) in the NINDS rt-PA stroke trial.
Therateof symptomaticintracerebralhemorrhage(6.3%)inIMS
subjects was similar to that of rt-PA-treated subjects (6.6%) but
higher than the rate in placebo-treated subjects (1.0%,p =0.018).
The rates of intracerebral hemorrhage were similar in all groups
but IMS subjects had a signiﬁcantly better outcome at 3months
than NINDS placebo-treated subjects (IMS Study Investigators,
2004).
The IMS-II trial found combined thrombolysis (IV+IA) to be
more beneﬁcial in acute stroke patients. Additional US therapy
was also used in this trial to dissolve the thrombus (IMS II Trial
Investigators, 2007; Tomsick et al., 2008). The trial involved rela-
tively few patients. Out of 73 IV (0.6mg/kg over 30min) treated
patients 50 received additional IA thrombolysis (max. 22mg IA)
and 34 underwent low energy US therapy as well. The mortality
rate was 16% and the rate of intracranial hemorrhage was 9.9%
in the IMS-II subjects. Patients undergoing combined thrombol-
ysis showed signiﬁcantly better outcome than the placebo group,
and better outcome than the rt-PA treated group of the NINDS
trial did.
MECHANICAL THROMBECTOMY
The IV thrombolysis does not always result in revasculariza-
tion and clinical improvement. The success rates of the IV rt-PA
treatment, based on anatomical location, are the following:
• Basilar artery: 30%
• Terminal part of the ICA: 6%
• M1 part of the MCA: 30%
• M2 part of the MCA: 44%
• Tandem ICA and MCA occlusion: 27% (Alexandrov, 2010b)
The failure of therapy can not solely be explained by the size of
the thrombus. The composition of the thrombus also plays a role,
because an arteriosclerotic plaque cannot be dissolved either by
rt-PAorbyanyotherthrombolyticdrug.Pharmacologicalthrom-
bolysis is more effective in case of distal occlusions (e.g., small
branchesoftheMCA),whilemechanicaldevicesaremoreusefulin
proximalmainstemocclusions.Themechanicalembolusremoval
in cerebral ischemia (MERCI) technique and device removes the
embolus from the blood vessel, like a corkscrew.
Mechanical embolectomy can be beneﬁcial if:
• the patient is excluded from the pharmacological thrombolysis
(e.g., after surgery)
• pharmacological thrombolysis did not lead to recanalization
• the patient suffers from coagulopathy
• the thrombus is calciﬁed
• beyond the 3-h time window
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Disadvantages of MERCI:
• difﬁcult to reach the thrombus in sclerotic arteries
• dissection or perforation of the vessels can occur
• the thrombus might break into parts and cause distal occlusion
Mechanical embolus removal in cerebral ischemia was the ﬁrst
device approved by FDA in 2004. Since then more than 10,000
devices are in use worldwide, and many variants have been pro-
duced. The principle behind this intervention is that a MERCI
micro-catheter (thin metal spiral) goes through the thrombus, a
balloon is blown up distally from the thrombus and the device
removes the blood clot. The balloon is used for preventing distal
embolization (Alexandrov, 2010b).
In the MERCI-I trial 28 patients were treated with this tech-
nique. Sixty-four percent of the patients had successful recanal-
ization and nine (32%) out of the recanalized patients showed
signiﬁcantclinicalimprovement,reaching0–2pointsonthemod-
iﬁed Rankin Scale. In the MERCI-II trial partial or complete
recanalizationwasachievedinapproximatelyhalf(48%)ofthe141
treated patients. Clinically signiﬁcant procedural complications
occurred in 10 (7%) patients. Clinically symptomatic intracranial
bleeding occurred in 7.8% of the patients. Patients undergoing
successfulrecanalizationshowedsigniﬁcantlybetterimprovement
reaching 0–2 scores on the modiﬁed Rankin Scale at the 3-month
follow-up. The clinical improvement was 46% if recanalization
was successful and only 10% if recanalization failed (p =0.001).
Mortality rates were better if recanalization was successful com-
paredtothosewhenrecanalizationfailed(32vs.54%;Smithetal.,
2008a).
Mechanical embolus removal in cerebral ischemia showed to
be particularly effective in case of main stem occlusions. Fifty-
three percent recanalization rate was achieved with MERCI for
internal carotid occlusions and 39% of these cases showed good
clinical outcome (reaching 0–2 scores on the modiﬁed Rankin
Scale). In the cases of internal carotid occlusion of those patients
who failed the MERCI revascularization procedure only 3% had
favorable outcome. Mortality rate was 30% in the group with suc-
cessfulrecanalizationand73%intheICAgroupwithoutsuccessful
recanalization.
In the Multi-MERCI trial if recanalization failed in response to
the IV rt-PA treatment mechanical thrombectomy was applied
(131 patients). Recanalization was successful in 75 of 131
(57.3%) cases. Additional methods (IA thrombolysis) increased
the recanalization rate to approximately 70%. Favorable clinical
outcomes (0–2 points at the modiﬁed Rankin Scale) occurred
in 36% and mortality was 34%; both outcomes were signiﬁ-
cantly related to vascular recanalization. Symptomatic intracere-
bral hemorrhage occurred in 16 patients (9.8%). Clinically signif-
icant procedural complications occurred in nine (5.5%) patients
(Flint et al., 2007; Smith et al., 2008a,b; Nogueira et al., 2009; Shi
et al.,2010).
The so-called Penumbra aspiration device was approved by
FDA in 2008. It consists of four micro-catheters, with different
sizes,accordingtothesizeofdifferentarteries.Thedevicedestructs
and aspirates the thrombus. Two trials have already proved the
effectiveness of the Penumbra device when used within the ﬁrst
8h of acute stroke,in case of patients who score higher than eight
points on the NIHSS (Penumbra Pivotal Stroke Trial Investiga-
tors, 2009). The Penumbra device achieved recanalization in 80%
of the 125 patients and 25% of the patients had 0–2 points on
the modiﬁed Rankin Scale 3months after the procedure. The rate
of symptomatic intracerebral bleedings was 2% and the 3-month
mortalityratewas30%.Whilethe“corkscrew”devices,likeMERCI
go through the thrombus, most of the aspiration devices, like
Penumbra, are applied proximal to the thrombus; this decreases
the risk of embolization.
Many other devices have been developed so far. One of them is
the Catch Thromb-embolectomy System, which is a“basket-like”
4mmequipment.ThePhenoxbloodclotremoveractslikeabrush
on a ﬂexible wire, containing brush-microﬁlaments. All these
attempts prove that there is no universal device able to remove
all types of thrombus. Furthermore, a successful recanalization
does not always automatically result in obvious clinical improve-
ment. However, the analysis of more than 1000 acute stroke cases
(33 trials) conﬁrmed that mechanical recanalization increases the
chance of good outcome.
Mechanical devices have several key advantages:
• recanalization occurs in approximately half of the treated
patients (conﬁrmed by angiography)
• recanalization occurs without the disruption of blood–brain
barrier
• no neurotoxicity (e.g., rt-PA is neurotoxic).
There are, however, some disadvantages to these techniques:
• they require an experienced interventional neuro-radiologist
• the devices are expensive
• they increase the risk of bleeding during the procedure.
Ongoing randomized trials (Khatri et al.,2008)areexpectedto
better deﬁne the role of these mechanical devices in the manage-
ment of acute ischemic stroke magnetic resonance and recanal-
ization of stroke clot using embolectomy (MR-RESCUE) and
IMS-III.
At this moment, pharmacological and mechanical stroke
treatment strategies are considered to be complementary.
STENTING IN ACUTE ISCHEMIC STROKE
There are only few studies investigating the utility of intracranial
stents for the treatment of acute ICA occlusion. An FDA trial,
including 20 patients reported the effectiveness and safety of this
procedure used in the ﬁrst 8h of acute stroke. Recanalization was
successful in half of the patients. There was one symptomatic and
twoasymptomaticintracranialhemorrhages.Onemonthafterthe
procedure nine patients (45%) scored <1 and 60% of the patients
scored<3onthemodiﬁedRankinScale(Levyetal.,2009).Inacute
stenting it is difﬁcult to pass through the atherosclerotic carotid
bifurcation. The concomitant antiplatelet therapy increases the
risk of hemorrhagic transformation or the risk of bleeding caused
by reperfusion. In a study of 25 patients 23 were successfully
recanalized. One bleeding and one carotid dissection occurred.
No data are available regarding the clinical outcomes (Jovin et al.,
2005).
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TRIALS COMBINING PHARMACOLOGICAL THROMBOLYSIS
WITH MECHANICAL RECANALIZATION DEVICES
The ongoing IMS-III trial is investigating whether a combined IV
and IA thrombolysis is superior to standard IV (standard dose of
0.9mg/kg)rt-PAtherapyaloneifitisinitiatedwithintheﬁrst3hof
acute stroke. The combined IV/IA group will receive a lower dose
of rt-PA (0.6mg/kg, 60mg max.) over 40min followed by imme-
diate angiography. If the thrombus is resolved, no additional IA
therapyisadministered.If theocclusionisstillpresent,thethrom-
bolysis will be completed by IA treatment (max. dose of 22mg of
rt-PA). The IA treatment must be started within the ﬁrst 5h and
mustbecompletedwithintheendof theseventhhourof theacute
stroke.IAthrombolysismightbecombinedwithlow-intensityUS
and thrombus-removal device as well. The clinical outcome is cal-
culatedbythemodiﬁedRankinScale3monthsaftertheprocedure
(Khatri et al.,2008).
The ongoing MR-RESCUE trial is evaluating the efﬁcacy of the
standard medical thrombolysis in case of proximal main branch
occlusion in the anterior circulation compared to the efﬁcacy of
mechanical thrombectomy (either with MERCI or Penumbra, in
the ﬁrst 8h of acute stroke).
Those patients who arrive in the ﬁrst 4.5h of stroke
might undergo standard IV thrombolysis before the mechanical
thrombectomy. The outcome is evaluated with modiﬁed Rankin
Scale 3months after stroke3.
The DAWN trial (DWI/PWI and CTP assessment in the
triage of wake-up and late presenting strokes undergoing neuro-
intervention) selects patients according to the MRI or CT perfu-
sion images more than 8h after the onset of stroke. Patients with
witnessedornon-witnessed(includingwake-up)strokeswith“last
timeseenwell”between7and23h,havingalargearterialocclusion
in the anterior circulation are selected. The treatment is initiated
between 8 and 24h. Results will be evaluated by the modiﬁed
Rankin Scale 3months after stroke4.
IMPROVING PERFUSION BY MODULATING GLOBAL
REPERFUSION OR BY TRANS-ARTERIAL RETROGRADE
REPERFUSION TECHNIQUE
Theprinciplebehindthisstrategyistoincreasebloodﬂowthrough
the lepto-meningeal arteries or through the collaterals of the cir-
cle of Willis. This can be accomplished by pharmacological (IV
phenyl-epinephrine infusion) therapy or by a mechanical device.
Thesafetyandefﬁcacyof neuroﬂo™ technologyinischemicstroke
(SENTIS) trial randomized subjects within the ﬁrst 14h of acute
stroke. They tried to achieve beneﬁcial outcome by inserting an
intra-aortic balloon under the region of the renal arteries to
increase intracerebral blood ﬂow through the collaterals. The
results were compared to conventional medical therapy alone5.
Enrollment was completed in 2010, but only preliminary data
from 2008 are available at the moment: adverse events (fatal and
non-fatal) were found to appear equally (34%) in both the con-
trol and the treated groups. However, mortality was signiﬁcantly
3www.strokecenter.org/trials/TrialDetail.aspx?tid(559
4www.strokecenter.org/trials/TrialDetail.aspx?tid(960
5www.strokecenter.org/trials/TrialDetail.aspx?tid(618
lowerforthetreatedpopulation(6.4%)vs.thecontrolpopulation
(14.9%), with more stroke progression (8.5%) and hemorrhagic
transformationof thestrokearea(4.3%)inthecontrolpopulation
(Uﬂacker et al., 2008).
NEUROPROTECTION
There are more than 100 medications that reached clinical phase
aftertheyhavebeenproventobeeffectiveinanimalmodels.None
of them has proved to be effective in human trials yet. Neuropro-
tectants would have the most clinical utility if they could be used
for both ischemic and hemorrhagic strokes early at the scene by
the paramedics (Danton and Dietrich, 2004).
“OPTIMAL” STROKE MANAGEMENT
Thesuccessof recanalizationdoesnotonlydependontheefﬁcacy
of the thrombolysis or the mechanical thrombectomy but also on
the organization of the stroke units. All elements of the“chain of
stroke management”must be appropriately controlled in order to
increasethenumberof patientswhoaresuitableforrecanalization
therapy. The elements are the following: does the patient recog-
nize the symptoms of stroke? – Does the patient know about the
time window? – Do stroke patients have priority transport with
advanced notiﬁcation to the hospital? – Are pre- and in-hospital
pathways well organized? – Does the hospital have a stroke unit?
Why are stroke units special? International, multicenter, ran-
domized clinical trials have proven that treatment provided in
stroke units decreases the risk of death and severe disability by
minimum 25% (Stroke Unit Trialists’ Collaboration, 2000). The
Cochrane analyses conﬁrmed that patients treated in stroke units
(independent of age, gender, or stroke type) have a signiﬁcantly
better chance to be alive 1year after the stroke and to live at home
instead of becoming severely disabled compared to patients who
FIGURE2|P atients who are alert and have a stable cardio-respiratory
status must be transferred to the CT directly. Unstable patients should
receive emergency therapy ﬁrst. If the thrombolysis cannot be done due to
the results of imaging or other criteria, the patient must be transferred to
the stroke unit. If thrombolysis is not contraindicated according to the
imaging, it must be started as soon as possible. All acute stroke patients
should be treated in stroke unit regardless whether they have already
received thrombolysis or not.
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FIGURE 3 |The future of acute stroke therapy. A neuroprotective drug is
administered on the site (not yet available).
werenottreatedinsuchstrokeunits.Themostimportantelements
of stroke units are (Alberts et al., 2005):
• experienced physicians, nurses, and physiotherapists, who are
familiar with stroke management
• monitoring for cardio-respiratory status
• protocolized stroke management
• integrated emergency system and well organized in-hospital
management
• laboratory and CT available around the clock
A personal“vision”about the future of stroke management:
• “Mobile CT” could differentiate ischemic strokes from hemor-
rhagic ones at the scene
• Neuroprotective agents (with proven effect both in ischemic
and hemorrhagic stroke) could be given by paramedics before
arrival to the stroke unit
• Alert patients with stable cardio-respiratory status should be
transferred directly to the CT. The neurological examination
andbloodsamplingshouldbeperformedattheradiology(CT)
area to save time (Figure 2)
• Within the 3 or 4.5-h time window thrombolysis should be
started IV in case of large vessel occlusion (both large vessel
andMCAbranch),buttheinterventionalteamshouldalsopre-
pareforthepossibleIAmechanicalbridgingtherapy.Therefore,
if the IV procedure fails to result in clinical improvement, the
neurologist may individually decide on continuing the throm-
bolysis IA or on applying a mechanical removal device. All of
these methods might be combined (Figure 3)
• Patients both with IV or IA thrombolysis must be observed
at an intensive care unit for 72h regardless of the success of
recanalization
• Rehabilitation must already be started at the stroke unit and
should be continued at the rehabilitation department/hospital.
SUMMARY
Successful acute stroke therapy can only be achieved by well
organized patient pathways. The success depends on the early
recognition of the alarming symptoms, on well/organized pre-
and in-hospital patient management, on the individual decisions
over the therapeutic modality, on the detailed monitoring in the
strokeunitsandonefﬁcientrehabilitation.Everycomponentmust
be well organized,because the strength of the chain is determined
by the weakest element.
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